Surgery Partners (NASDAQ:SGRY – Get Free Report) released its earnings results on Monday. The company reported $0.13 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.19 by ($0.06), Briefing.com reports. Surgery Partners had a negative net margin of 5.57% and a positive return on equity of 2.51%. The business had revenue of $821.50 million for the quarter, compared to analysts’ expectations of $823.55 million. During the same quarter in the previous year, the business posted $0.19 earnings per share. Surgery Partners’s revenue for the quarter was up 6.6% on a year-over-year basis. Surgery Partners updated its FY 2025 guidance to EPS.
Surgery Partners Trading Down 24.0%
Surgery Partners stock traded down $5.16 during trading hours on Monday, hitting $16.34. The company had a trading volume of 3,918,663 shares, compared to its average volume of 1,372,712. The firm has a market cap of $2.09 billion, a P/E ratio of -11.42 and a beta of 1.85. The company has a 50-day moving average price of $21.62 and a two-hundred day moving average price of $22.18. Surgery Partners has a 1 year low of $16.31 and a 1 year high of $31.89. The company has a debt-to-equity ratio of 1.10, a quick ratio of 1.78 and a current ratio of 1.93.
Insider Buying and Selling
In other Surgery Partners news, insider Harrison R. Bane sold 9,339 shares of the company’s stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $22.48, for a total value of $209,940.72. Following the completion of the sale, the insider directly owned 117,181 shares in the company, valued at approximately $2,634,228.88. This represents a 7.38% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.70% of the stock is owned by insiders.
Hedge Funds Weigh In On Surgery Partners
Wall Street Analyst Weigh In
A number of research firms recently weighed in on SGRY. JPMorgan Chase & Co. initiated coverage on Surgery Partners in a research report on Thursday, September 18th. They set a “neutral” rating and a $27.00 price objective for the company. Bank of America started coverage on shares of Surgery Partners in a report on Monday, July 28th. They set a “buy” rating and a $28.00 price target on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $36.00 price objective on shares of Surgery Partners in a research report on Tuesday, October 7th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Surgery Partners in a report on Wednesday, October 8th. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $31.14.
Check Out Our Latest Stock Report on Surgery Partners
Surgery Partners Company Profile
Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.
Featured Stories
- Five stocks we like better than Surgery Partners
- How to Invest in Biotech Stocks
- 5 Defensive Consumer Plays to Watch If Markets Keep Slipping
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Analysts Keep Raving Over AppLovin: Targets Rise Post-Earnings
- How to Invest in Tech StocksĀ and Top Tech Stocks to Consider
- Is Airbnb Stock a Buy After Q3 Earnings Miss?
Receive News & Ratings for Surgery Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surgery Partners and related companies with MarketBeat.com's FREE daily email newsletter.
